Inflammatory profile in cervical cancer: influence of purinergic signaling and possible therapeutic targets.

ABSTRACT

INTRODUCTION AND OBJECTIVE: Cervical cancer is the fourth most prevalent type of cancer in the world. The tumor microenvironment of this disease is associated with the production of several cytokines, pro and anti-inflammatory, and with the purinergic signaling system so that changes in these components are observed throughout the pathological process. The aim of this review is to understand the pathophysiology of cervical cancer based on immunological processes and purinergic signaling pathways, in addition to suggesting possibilities of therapeutic targets. MATERIALS AND METHODS: To make up this review, studies covering topics of cervical cancer, inflammation and purinergic system were selected from the Pubmed. RESULTS: The main pro-inflammatory cytokines involved are IL-17, IL-1ß, IL-6, and IL-18, and among the anti-inflammatory ones, IL-10 and TGF-ß stand out. As new therapeutic targets, P2X7 and A2A receptors have been suggested, since blocking P2X7 would lead to reduced release of pro-inflammatory cytokines, and blocking A2A would increase activation of cytotoxic T lymphocytes in the context of tumor combat. The association between the immune system and the purinergic system, already known in other types of disease, also presents possibilities for a better understanding of biomolecular processes and therapeutic possibilities in the context of cervical cancer.